Market Research Report: Global Mumps Prophylactic & Therapeutic Market
Report Overview
This report provides a strategic analysis of the global market for mumps-related pharmaceutical products, encompassing both prophylactic vaccines and therapeutic agents used for outbreak management and treatment of complications. The market is analyzed from 2025 to 2036, covering status, forecast, competitive landscape, and key strategic insights.
Executive Summary
The global Mumps Prophylactic & Therapeutic market is valued at an estimated USD XX million in 2025 and is projected to reach USD YY million by 2036, growing at a compound annual growth rate (CAGR) of ZZ% during the forecast period (2026-2036). Growth is primarily driven by recurring mumps outbreaks in vaccinated populations, the expansion of National Immunization Programs (NIPs) in emerging economies, and the development of next-generation vaccine candidates. The therapeutic segment remains niche, focused on managing symptoms and complications.
Market Segmentation Analysis
1. By Product Type:
-
Prophylactic Vaccines (Dominant Segment):
-
Monovalent Mumps Vaccines: Rarely used; primarily for outbreak control in specific settings.
-
Combination Vaccines (MMR & MMRV): The standard of care globally. Includes vaccines based on different strains:
-
Jeryl Lynn Strain (Used in M-M-R II by Merck)
-
RIT 4385 Strain (Derived from Jeryl Lynn, used in Priorix by GSK)
-
L-Zagreb Strain (Used in some markets)
-
Urabe AM9 Strain (Use is declining due to higher parotitis risk).
-
-
-
Therapeutic Agents (Supportive Care):
-
Analgesics & Antipyretics: For symptom management (pain, fever).
-
Corticosteroids: Investigational/used in severe inflammatory complications (e.g., orchitis, meningoencephalitis).
-
Immunoglobulins: Limited use in specific outbreak contexts for post-exposure prophylaxis in high-risk individuals.
-
2. By End User:
-
Pediatric Population: Primary vaccination schedule (12-15 months, 4-6 years).
-
Adolescent & Adult Population: Catch-up vaccination, third-dose recommendations for outbreak control.
-
High-Risk Groups: Healthcare workers, military personnel, college students, and immunocompromised individuals (where applicable).
3. By Distribution Channel:
-
Public Sector/Government Programs: The largest channel, procuring vaccines for NIPs via tenders.
-
Private Sector: Includes private pediatric clinics, travel medicine clinics, and corporate wellness programs.
-
Hospital Pharmacies: For therapeutic agents and outbreak response doses.
Regional Analysis
-
North America: A significant market characterized by high routine vaccination coverage, but with periodic outbreaks driving demand for third-dose campaigns. The U.S. is the primary contributor, with both public (CDC) and private sector demand.
-
Europe: Mature market with high MMR coverage, though outbreaks in the UK and other regions have prompted revised immunization strategies. The EU4 (Germany, France, Italy, Spain) and the UK are key markets.
-
Asia-Pacific: The fastest-growing and largest volume market, driven by expansive NIPs in China and India, and catch-up campaigns in Japan and South Korea. Local manufacturers play a crucial role.
-
Latin America: Strong market with well-established NIPs incorporating MMR. Brazil, Mexico, and Argentina are key countries.
-
Middle East & Africa: Variable coverage. GCC nations have strong programs, while other regions rely on Gavi-supported immunization initiatives, presenting growth opportunities.
Competitive Landscape & Key Players
The vaccine market is an oligopoly dominated by a few multinational and several major emerging market manufacturers.
-
Merck & Co., Inc. (M-M-R II, ProQuad - Jeryl Lynn strain)
-
GlaxoSmithKline plc (Priorix, Priorix-Tetra - RIT 4385 strain)
-
Sanofi Pasteur (historical player, with divested assets)
-
Serum Institute of India Pvt. Ltd. (Major supplier to UNICEF and Gavi)
-
Bharat Biotech International Limited
-
Sinovac Biotech Ltd.
-
China National Pharmaceutical Group Corporation (Sinopharm) (Beijing Tiantan Biological)
-
Zydus Cadila Healthcare Limited (Zydus Lifesciences)
-
Other Notable: Beijing Minhai Biotechnology, KM Biologics (Japan), GreenCross Corp (South Korea), Indian Immunologicals Ltd., Prometheon Pharma (development-stage).
Strategic Analysis Frameworks
Porter’s Five Forces Analysis
-
Competitive Rivalry: High among vaccine manufacturers. Intense competition for tenders in the public sector, though the market is consolidated with high barriers. Strain efficacy data and pricing are key differentiators.
-
Bargaining Power of Suppliers: Low to Moderate. Raw materials (eggs, cell cultures) are commoditized. However, suppliers of specialized adjuvants or vial components hold moderate power.
-
Bargaining Power of Buyers: Very High for Public Buyers. Entities like UNICEF, PAHO, and national governments wield enormous pricing power through volume tenders. Moderate for private sector buyers.
-
Threat of New Entrants: Low. Extremely high barriers: complex and lengthy manufacturing process, stringent WHO prequalification/FDA approval, massive capital investment, and established procurement relationships.
-
Threat of Substitutes: Low. No functional substitute for vaccination exists. Within the market, different vaccine strains or combination formats (MMR vs. MMRV) act as intra-category substitutes.
SWOT Analysis
-
Strengths: Vaccination is the only effective prevention method; vaccines are highly cost-effective; strong integration into global NIPs; long product lifecycles.
-
Weaknesses: Waning immunity leading to outbreaks in young adults; rare adverse event concerns impacting public confidence; low commercial incentive for novel therapeutic drug development.
-
Opportunities: Potential for improved vaccines with longer-lasting immunity; expansion of immunization programs in low-and-middle-income countries (LMICs); development of mumps-specific monoclonal antibodies (therapeutics).
-
Threats: Vaccine hesitancy and misinformation; extreme price pressure in public tenders squeezing margins; liability risks; pandemic-related disruption to routine immunization.
Trend Analysis
-
Outbreak Response & Revised Guidelines: Increasing adoption of a third MMR dose recommendations in outbreak settings by public health authorities, creating intermittent demand surges.
-
Focus on Waning Immunity: R&D into next-generation vaccine candidates (e.g., novel adjuvants, different strain platforms) to address the durability of immune response.
-
Combination Vaccine Dominance: Sustained preference for MMR/MMRV over monovalent products for programmatic efficiency.
-
Localization of Vaccine Manufacturing: Growing capability and market share of manufacturers in Asia-Pacific and other regions, supported by WHO prequalification.
-
Digital Surveillance & Forecasting: Use of data analytics to predict outbreak risks and optimize vaccine stockpiling and distribution.
Market Drivers & Challenges
-
Drivers:
-
Recurrent mumps outbreaks among vaccinated adolescents and young adults.
-
Sustained global commitment to childhood immunization (Gavi, WHO EPI).
-
Growing birth cohorts in emerging economies.
-
Increasing awareness and public health mandates for college entrants and healthcare workers.
-
-
Challenges:
-
Waning Vaccine Immunity: Undermines confidence and necessitates complex booster policies.
-
Manufacturing Complexity & Capacity: Live-attenuated vaccine production is biological, variable, and difficult to scale rapidly.
-
Vaccine Hesitancy: Impacts coverage rates and herd immunity thresholds.
-
Commoditization & Margin Pressure: Especially in high-volume, publicly funded markets.
-
Value Chain Analysis
-
Virus Strain Development & Master Seed Bank: Maintenance of attenuated viral strains under GMP.
-
Manufacturing & Fill-Finish: Complex process involving cell culture, virus propagation, harvesting, purification, formulation, and lyophilization.
-
Quality Control & Lot Release: Rigorous testing for potency, sterility, and safety. Each lot requires approval by the national regulatory authority (NRA) or WHO for prequalified products.
-
Regulatory Affairs & Prequalification: Achieving WHO prequalification is critical for supplying to UN agencies and many LMICs.
-
Procurement & Supply Chain: Managed by governments, UN agencies (UNICEF), and NGOs. Requires sophisticated cold chain logistics.
-
Administration & Surveillance: Delivery through public health clinics and private providers, coupled with pharmacovigilance.
Quick Recommendations for Stakeholders
-
For Vaccine Manufacturers: Invest in R&D for next-generation mumps vaccine candidates with improved durability. Diversify manufacturing geographically to improve supply resilience and access to regional markets. Develop robust health economics data to support the value of third-dose recommendations to payers.
-
For Public Health Agencies & Governments: Strengthen routine immunization systems and surveillance to quickly detect outbreaks. Pre-position contractual agreements for outbreak response doses. Invest in public communication to combat misinformation and maintain high baseline coverage.
-
For Healthcare Providers: Actively recommend and administer catch-up MMR vaccinations to adolescents and young adults, especially in high-risk settings (colleges, military). Be prepared to implement public health guidance on third doses during outbreaks.
-
For Investors: The market is stable with recurring demand but is subject to low margins in the commodity-like public segment. Investment opportunities lie in companies with: 1) innovative pipeline candidates addressing waning immunity, 2) strong positions in growing private pediatric markets in APAC, or 3) vertically integrated, low-cost manufacturing for the public sector.
-
For New Entrants/Biotechs: The high barrier for vaccine entry makes this challenging. A more viable path may be developing mumps-specific therapeutics (e.g., antivirals, monoclonal antibodies) for severe cases, an underserved niche with potential for high value.
Table of Contents
Global Mumps Drug Market Research Report 2026
1 Industry Overview of Mumps Drug
1.1 Definition and Specifications of Mumps Drug
1.1.1 Definition of Mumps Drug
1.1.2 Specifications of Mumps Drug
1.2 Classification of Mumps Drug
1.2.1 RIT 4385
1.2.2 Schwarz
1.2.3 Wistar RA 27/3
1.2.4 Others
1.3 Applications of Mumps Drug
1.3.1 Hospital
1.3.2 Clinic
1.3.3 Others
1.4 Market Segment by Regions
1.4.1 North America
1.4.2 Europe
1.4.3 China
1.4.4 Japan
1.4.5 Southeast Asia
1.4.6 India
2 Manufacturing Cost Structure Analysis of Mumps Drug
2.1 Raw Material and Suppliers
2.2 Manufacturing Cost Structure Analysis of Mumps Drug
2.3 Manufacturing Process Analysis of Mumps Drug
2.4 Industry Chain Structure of Mumps Drug
3 Technical Data and Manufacturing Plants Analysis of Mumps Drug
3.1 Capacity and Commercial Production Date of Global Mumps Drug Major Manufacturers
3.2 Manufacturing Plants Distribution of Global Mumps Drug Major Manufacturers
3.3 R&D Status and Technology Source of Global Mumps Drug Major Manufacturers
3.4 Raw Materials Sources Analysis of Global Mumps Drug Major Manufacturers
4 Global Mumps Drug Overall Market Overview
4.1 E Overall Market Analysis
4.2 Capacity Analysis
4.2.1 E Global Mumps Drug Capacity and Growth Rate Analysis
4.2.2 Mumps Drug Capacity Analysis (Company Segment)
4.3 Sales Analysis
4.3.1 E Global Mumps Drug Sales and Growth Rate Analysis
4.3.2 Mumps Drug Sales Analysis (Company Segment)
4.4 Sales Price Analysis
4.4.1 E Global Mumps Drug Sales Price
4.4.2 Mumps Drug Sales Price Analysis (Company Segment)
5 Mumps Drug Regional Market Analysis
5.1 North America Mumps Drug Market Analysis
5.1.1 North America Mumps Drug Market Overview
5.1.2 North America E Mumps Drug Local Supply, Import, Export, Local Consumption Analysis
5.1.3 North America E Mumps Drug Sales Price Analysis
5.1.4 North America Mumps Drug Market Share Analysis
5.2 Europe Mumps Drug Market Analysis
5.2.1 Europe Mumps Drug Market Overview
5.2.2 Europe E Mumps Drug Local Supply, Import, Export, Local Consumption Analysis
5.2.3 Europe E Mumps Drug Sales Price Analysis
5.2.4 Europe Mumps Drug Market Share Analysis
5.3 China Mumps Drug Market Analysis
5.3.1 China Mumps Drug Market Overview
5.3.2 China E Mumps Drug Local Supply, Import, Export, Local Consumption Analysis
5.3.3 China E Mumps Drug Sales Price Analysis
5.3.4 China Mumps Drug Market Share Analysis
5.4 Japan Mumps Drug Market Analysis
5.4.1 Japan Mumps Drug Market Overview
5.4.2 Japan E Mumps Drug Local Supply, Import, Export, Local Consumption Analysis
5.4.3 Japan E Mumps Drug Sales Price Analysis
5.4.4 Japan Mumps Drug Market Share Analysis
5.5 Southeast Asia Mumps Drug Market Analysis
5.5.1 Southeast Asia Mumps Drug Market Overview
5.5.2 Southeast Asia E Mumps Drug Local Supply, Import, Export, Local Consumption Analysis
5.5.3 Southeast Asia E Mumps Drug Sales Price Analysis
5.5.4 Southeast Asia Mumps Drug Market Share Analysis
5.6 India Mumps Drug Market Analysis
5.6.1 India Mumps Drug Market Overview
5.6.2 India E Mumps Drug Local Supply, Import, Export, Local Consumption Analysis
5.6.3 India E Mumps Drug Sales Price Analysis
5.6.4 India Mumps Drug Market Share Analysis
6 Global E Mumps Drug Segment Market Analysis (by Type)
6.1 Global E Mumps Drug Sales by Type
6.2 Different Types of Mumps Drug Product Interview Price Analysis
6.3 Different Types of Mumps Drug Product Driving Factors Analysis
6.3.1 RIT 4385 Growth Driving Factor Analysis
6.3.2 Schwarz Growth Driving Factor Analysis
6.3.3 Wistar RA 27/3 Growth Driving Factor Analysis
6.3.4 Others Growth Driving Factor Analysis
7 Global E Mumps Drug Segment Market Analysis (by Application)
7.1 Global E Mumps Drug Consumption by Application
7.2 Different Application of Mumps Drug Product Interview Price Analysis
7.3 Different Application of Mumps Drug Product Driving Factors Analysis
7.3.1 Hospital of Mumps Drug Growth Driving Factor Analysis
7.3.2 Clinic of Mumps Drug Growth Driving Factor Analysis
7.3.3 Others of Mumps Drug Growth Driving Factor Analysis
8 Major Manufacturers Analysis of Mumps Drug
8.1 Beijing Minhai Biotechnology Co., Ltd
8.1.1 Company Profile
8.1.2 Product Picture and Specifications
8.1.2.1 Product A
8.1.2.2 Product B
8.1.3 Beijing Minhai Biotechnology Co., Ltd Mumps Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.1.4 Beijing Minhai Biotechnology Co., Ltd Mumps Drug Business Region Distribution Analysis
8.2 Beijing Tiantan Biological Products Co., Ltd.
8.2.1 Company Profile
8.2.2 Product Picture and Specifications
8.2.2.1 Product A
8.2.2.2 Product B
8.2.3 Beijing Tiantan Biological Products Co., Ltd. Mumps Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.2.4 Beijing Tiantan Biological Products Co., Ltd. Mumps Drug Business Region Distribution Analysis
8.3 China National Pharmaceutical Group Corporation
8.3.1 Company Profile
8.3.2 Product Picture and Specifications
8.3.2.1 Product A
8.3.2.2 Product B
8.3.3 China National Pharmaceutical Group Corporation Mumps Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.3.4 China National Pharmaceutical Group Corporation Mumps Drug Business Region Distribution Analysis
8.4 GlaxoSmithKline Plc
8.4.1 Company Profile
8.4.2 Product Picture and Specifications
8.4.2.1 Product A
8.4.2.2 Product B
8.4.3 GlaxoSmithKline Plc Mumps Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.4.4 GlaxoSmithKline Plc Mumps Drug Business Region Distribution Analysis
8.5 Organic Vaccines
8.5.1 Company Profile
8.5.2 Product Picture and Specifications
8.5.2.1 Product A
8.5.2.2 Product B
8.5.3 Organic Vaccines Mumps Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.5.4 Organic Vaccines Mumps Drug Business Region Distribution Analysis
8.6 Prometheon Pharma, LLC
8.6.1 Company Profile
8.6.2 Product Picture and Specifications
8.6.2.1 Product A
8.6.2.2 Product B
8.6.3 Prometheon Pharma, LLC Mumps Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.6.4 Prometheon Pharma, LLC Mumps Drug Business Region Distribution Analysis
8.7 Sinovac Biotech Ltd.
8.7.1 Company Profile
8.7.2 Product Picture and Specifications
8.7.2.1 Product A
8.7.2.2 Product B
8.7.3 Sinovac Biotech Ltd. Mumps Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.7.4 Sinovac Biotech Ltd. Mumps Drug Business Region Distribution Analysis
8.8 Zydus Cadila Healthcare Limited
8.8.1 Company Profile
8.8.2 Product Picture and Specifications
8.8.2.1 Product A
8.8.2.2 Product B
8.8.3 Zydus Cadila Healthcare Limited Mumps Drug Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.8.4 Zydus Cadila Healthcare Limited Mumps Drug Business Region Distribution Analysis
9 Development Trend of Analysis of Mumps Drug Market
9.1 Global Mumps Drug Market Trend Analysis
9.1.1 Global Mumps Drug Market Size (Volume and Value) Forecast
9.1.2 Global Mumps Drug Sales Price Forecast
9.2 Mumps Drug Regional Market Trend
9.2.1 North America Mumps Drug Consumption Forecast
9.2.2 Europe Mumps Drug Consumption Forecast
9.2.3 China Mumps Drug Consumption Forecast
9.2.4 Japan Mumps Drug Consumption Forecast
9.2.5 Southeast Asia Mumps Drug Consumption Forecast
9.2.6 India Mumps Drug Consumption Forecast
9.3 Mumps Drug Market Trend (Product Type)
9.4 Mumps Drug Market Trend (Application)
10 Mumps Drug Marketing Type Analysis
10.1 Mumps Drug Regional Marketing Type Analysis
10.2 Mumps Drug International Trade Type Analysis
10.3 Traders or Distributors with Contact Information of Mumps Drug by Region
10.4 Mumps Drug Supply Chain Analysis
11 Consumers Analysis of Mumps Drug
11.1 Consumer 1 Analysis
11.2 Consumer 2 Analysis
11.3 Consumer 3 Analysis
11.4 Consumer 4 Analysis
12 Conclusion of the Global Mumps Drug Market Professional Survey Report
Methodology
Analyst Introduction
Data Source
List of Tables and Figures
Figure Picture of Mumps Drug
Table Product Specifications of Mumps Drug
Table Classification of Mumps Drug
Figure Global Production Market Share of Mumps Drug by Type in
Figure RIT 4385 Picture
Table Major Manufacturers of RIT 4385
Figure Schwarz Picture
Table Major Manufacturers of Schwarz
Figure Wistar RA 27/3 Picture
Table Major Manufacturers of Wistar RA 27/3
Figure Others Picture
Table Major Manufacturers of Others
Table Applications of Mumps Drug
Figure Global Consumption Volume Market Share of Mumps Drug by Application in
Figure Hospital Examples
Table Major Consumers in Hospital
Figure Clinic Examples
Table Major Consumers in Clinic
Figure Others Examples
Table Major Consumers in Others
Figure Market Share of Mumps Drug by Regions
Figure North America Mumps Drug Market Size (Million USD) (2013-2025)
Figure Europe Mumps Drug Market Size (Million USD) (2013-2025)
Figure China Mumps Drug Market Size (Million USD) (2013-2025)
Figure Japan Mumps Drug Market Size (Million USD) (2013-2025)
Figure Southeast Asia Mumps Drug Market Size (Million USD) (2013-2025)
Figure India Mumps Drug Market Size (Million USD) (2013-2025)
Table Mumps Drug Raw Material and Suppliers
Table Manufacturing Cost Structure Analysis of Mumps Drug in
Figure Manufacturing Process Analysis of Mumps Drug
Figure Industry Chain Structure of Mumps Drug
Table Capacity and Commercial Production Date of Global Mumps Drug Major Manufacturers
Table Manufacturing Plants Distribution of Global Mumps Drug Major Manufacturers
Table R&D Status and Technology Source of Global Mumps Drug Major Manufacturers
Table Raw Materials Sources Analysis of Global Mumps Drug Major Manufacturers
Table Global Capacity, Sales , Price, Cost, Sales Revenue (M USD) and Gross Margin of Mumps Drug E
Figure Global E Mumps Drug Market Size (Volume) and Growth Rate
Figure Global E Mumps Drug Market Size (Value) and Growth Rate
Table E Global Mumps Drug Capacity and Growth Rate
Table Global Mumps Drug Capacity (K Pcs) List (Company Segment)
Table E Global Mumps Drug Sales (K Pcs) and Growth Rate
Table Global Mumps Drug Sales (K Pcs) List (Company Segment)
Table E Global Mumps Drug Sales Price (USD/Pcs)
Table Global Mumps Drug Sales Price (USD/Pcs) List (Company Segment)
Figure North America Capacity Overview
Table North America Supply, Import, Export and Consumption (K Pcs) of Mumps Drug E
Figure North America E Mumps Drug Sales Price (USD/Pcs)
Figure North America Mumps Drug Sales Market Share
Figure Europe Capacity Overview
Table Europe Supply, Import, Export and Consumption (K Pcs) of Mumps Drug E
Figure Europe E Mumps Drug Sales Price (USD/Pcs)
Figure Europe Mumps Drug Sales Market Share
Figure China Capacity Overview
Table China Supply, Import, Export and Consumption (K Pcs) of Mumps Drug E
Figure China E Mumps Drug Sales Price (USD/Pcs)
Figure China Mumps Drug Sales Market Share
Figure Japan Capacity Overview
Table Japan Supply, Import, Export and Consumption (K Pcs) of Mumps Drug E
Figure Japan E Mumps Drug Sales Price (USD/Pcs)
Figure Japan Mumps Drug Sales Market Share
Figure Southeast Asia Capacity Overview
Table Southeast Asia Supply, Import, Export and Consumption (K Pcs) of Mumps Drug E
Figure Southeast Asia E Mumps Drug Sales Price (USD/Pcs)
Figure Southeast Asia Mumps Drug Sales Market Share
Figure India Capacity Overview
Table India Supply, Import, Export and Consumption (K Pcs) of Mumps Drug E
Figure India E Mumps Drug Sales Price (USD/Pcs)
Figure India Mumps Drug Sales Market Share
Table Global E Mumps Drug Sales (K Pcs) by Type
Table Different Types Mumps Drug Product Interview Price
Table Global E Mumps Drug Sales (K Pcs) by Application
Table Different Application Mumps Drug Product Interview Price
Table Beijing Minhai Biotechnology Co., Ltd Information List
Table Product Overview
Table Beijing Minhai Biotechnology Co., Ltd Mumps Drug Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Beijing Minhai Biotechnology Co., Ltd Mumps Drug Business Region Distribution
Table Beijing Tiantan Biological Products Co., Ltd. Information List
Table Product Overview
Table Beijing Tiantan Biological Products Co., Ltd. Mumps Drug Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Beijing Tiantan Biological Products Co., Ltd. Mumps Drug Business Region Distribution
Table China National Pharmaceutical Group Corporation Information List
Table Product Overview
Table China National Pharmaceutical Group Corporation Mumps Drug Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure China National Pharmaceutical Group Corporation Mumps Drug Business Region Distribution
Table GlaxoSmithKline Plc Information List
Table Product Overview
Table GlaxoSmithKline Plc Mumps Drug Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure GlaxoSmithKline Plc Mumps Drug Business Region Distribution
Table Organic Vaccines Information List
Table Product Overview
Table Organic Vaccines Mumps Drug Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Organic Vaccines Mumps Drug Business Region Distribution
Table Prometheon Pharma, LLC Information List
Table Product Overview
Table Prometheon Pharma, LLC Mumps Drug Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Prometheon Pharma, LLC Mumps Drug Business Region Distribution
Table Sinovac Biotech Ltd. Information List
Table Product Overview
Table Sinovac Biotech Ltd. Mumps Drug Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Sinovac Biotech Ltd. Mumps Drug Business Region Distribution
Table Zydus Cadila Healthcare Limited Information List
Table Product Overview
Table Zydus Cadila Healthcare Limited Mumps Drug Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Zydus Cadila Healthcare Limited Mumps Drug Business Region Distribution
Figure Global Mumps Drug Market Size (K Pcs) and Growth Rate Forecast
Figure Global Mumps Drug Market Size (Million USD) and Growth Rate Forecast
Figure Global Mumps Drug Sales Price (USD/Pcs) Forecast
Figure North America Mumps Drug Consumption Volume (K Pcs) and Growth Rate Forecast
Figure China Mumps Drug Consumption Volume (K Pcs) and Growth Rate Forecast
Figure Europe Mumps Drug Consumption Volume (K Pcs) and Growth Rate Forecast
Figure Southeast Asia Mumps Drug Consumption Volume (K Pcs) and Growth Rate Forecast
Figure Japan Mumps Drug Consumption Volume (K Pcs) and Growth Rate Forecast
Figure India Mumps Drug Consumption Volume (K Pcs) and Growth Rate Forecast
Table Global Sales Volume (K Pcs) of Mumps Drug by Type
Table Global Consumption Volume (K Pcs) of Mumps Drug by Application
Table Traders or Distributors with Contact Information of Mumps Drug by Region
Market Segmentation Analysis
1. By Product Type:
-
Prophylactic Vaccines (Dominant Segment):
-
Monovalent Mumps Vaccines: Rarely used; primarily for outbreak control in specific settings.
-
Combination Vaccines (MMR & MMRV): The standard of care globally. Includes vaccines based on different strains:
-
Jeryl Lynn Strain (Used in M-M-R II by Merck)
-
RIT 4385 Strain (Derived from Jeryl Lynn, used in Priorix by GSK)
-
L-Zagreb Strain (Used in some markets)
-
Urabe AM9 Strain (Use is declining due to higher parotitis risk).
-
-
-
Therapeutic Agents (Supportive Care):
-
Analgesics & Antipyretics: For symptom management (pain, fever).
-
Corticosteroids: Investigational/used in severe inflammatory complications (e.g., orchitis, meningoencephalitis).
-
Immunoglobulins: Limited use in specific outbreak contexts for post-exposure prophylaxis in high-risk individuals.
-
2. By End User:
-
Pediatric Population: Primary vaccination schedule (12-15 months, 4-6 years).
-
Adolescent & Adult Population: Catch-up vaccination, third-dose recommendations for outbreak control.
-
High-Risk Groups: Healthcare workers, military personnel, college students, and immunocompromised individuals (where applicable).
3. By Distribution Channel:
-
Public Sector/Government Programs: The largest channel, procuring vaccines for NIPs via tenders.
-
Private Sector: Includes private pediatric clinics, travel medicine clinics, and corporate wellness programs.
-
Hospital Pharmacies: For therapeutic agents and outbreak response doses.
